Silk Road Medical (SILK) Stock Price, News & Analysis

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Silk Road Medical in the last twelve months. There are currently 2 sell ratings, 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" SILK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SILK, but not buy additional shares or sell existing shares.
View SILK analyst ratings or view top-rated stocks.

11 Wall Street research analysts have issued 12-month price objectives for Silk Road Medical's shares. Their SILK share price targets range from $8.00 to $47.00. On average, they anticipate the company's stock price to reach $22.55 in the next year. This suggests a possible upside of 7.9% from the stock's current price.
View analysts price targets for SILK or view top-rated stocks among Wall Street analysts.

Silk Road Medical's stock was trading at $12.27 on January 1st, 2024. Since then, SILK shares have increased by 70.3% and is now trading at $20.90.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 6th 2024.
View our SILK earnings forecast.

Silk Road Medical, Inc (NASDAQ:SILK) announced its quarterly earnings data on Tuesday, April, 30th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.04. The company had revenue of $48.50 million for the quarter, compared to the consensus estimate of $44.67 million. Silk Road Medical had a negative net margin of 29.02% and a negative trailing twelve-month return on equity of 35.12%. Silk Road Medical's quarterly revenue was up 20.9% on a year-over-year basis. During the same period in the previous year, the company posted ($0.43) earnings per share.

ETFs with the largest weight of Silk Road Medical (NASDAQ:SILK) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE) and Invesco Dorsey Wright Healthcare Momentum ETF (PTH).iShares U.S. Medical Devices ETF (IHI).

Silk Road Medical issued an update on its FY 2024 earnings guidance on Tuesday, April, 30th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $194.0 million-$198.0 million, compared to the consensus revenue estimate of $195.9 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Silk Road Medical investors own include RTX (RTX), Procter & Gamble (PG), Abbott Laboratories (ABT), Cisco Systems (CSCO), Pfizer (PFE), Edwards Lifesciences (EW), CSX (CSX), Thermo Fisher Scientific (TMO) and Alibaba Group (BABA).

Silk Road Medical (SILK) raised $75 million in an initial public offering (IPO) on Thursday, April 4th 2019. The company issued 4,700,000 shares at $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and BMO Capital Markets and Stifel were co-managers.

Silk Road Medical's stock is owned by many different retail and institutional investors. Top institutional shareholders include Wasatch Advisors LP (11.62%), BNP Paribas Financial Markets (0.33%), Assenagon Asset Management S.A. (0.11%) and Quantbot Technologies LP (0.06%). Insiders that own company stock include Andrew S Davis, Andrew S Davis, Elizabeth H Weatherman, Erica J Rogers, Erica J Rogers, Jack W Lasersohn, Kevin J Ballinger, Kevin M Klemz, Lucas W Buchanan, Marie L Jones, Richard Ruedy and Tony M Chou.
View institutional ownership trends.

Shares of SILK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.